Illuminating HER2 expression, transforming lives
Harnessing Antibody Scintigraphy for Precision Diagnostics in Breast Cancer and Beyond
Our challenge — identify the right patients at the right time
Breast cancer is the most frequently diagnosed cancer among women worldwide, with over 2.26 million new cases and nearly 685,000 deaths every year.
Notwithstanding advancements in targeted cancer treatments over the past decade, the scientific community faces challenges in identifying the right patients due to the lack of precise diagnostic technologies. Current methods, such as biopsies, are burdensome and lack comprehensive body information. Furthermore, patient monitoring throughout and post-treatment is compromised by invasive or imprecise methods.
Encouragingly, advancements in diagnostic technology are underway, promising expedited, safer, and more precise assessments. These innovations hold the potential to markedly enhance survival outcomes, particularly when complemented by tailored therapeutic interventions.
ABSCINT-HER2 PET scan confirms HER2 metastases in backbone, shoulder and legs. Uptake in kidneys and liver are due to the natural excretion of the PET tracer.
Our solution — illuminating HER2 expression, transforming lives
ABSCINT aims to address these challenges in HER2 cancers by pioneering advanced, non-invasive in vivo imaging diagnostic technologies that enhance specificity, precision, convenience, and safety for both patients and healthcare workers.
ABSCINT’s development of a specific anti-HER2 PET tracer facilitates whole-body imaging, enabling physicians to comprehensively evaluate disease heterogeneity, monitor progression, and gauge treatment efficacy. This innovation also opens the door to HER2 reclassification via image-guided biopsies, enhancing diagnostic accuracy and patient care.
Advantages for patients
ABSCINT specializes in developing in vivo imaging diagnostics, with a focus on cutting-edge positron emission tomography (PET) tracers leveraged by single-domain antibodies (sdAbs) as precision targeting agents.
Labeled with a short-half life radioisotope like gallium-68, sdAbs are administered intravenously to patients, where they specifically bind to surface proteins on aberrant cells.
This radiolabeling allows for precise visualization of targeted cells via PET scans, offering a detailed whole-body lesion map that surpasses the capabilities of traditional biopsies in detecting disease heterogeneity and monitoring treatment efficacy.
This innovative technology ensures rapid, comprehensive imaging results, enabling whole-body imaging within 60-90 minutes after injection, without necessitating patient hospitalization thanks to its quick clearance and fast radioactive decay. Moreover, the technology features very low radiation doses, eliminating the need for patient isolation and allowing multiple scans per patient, enhancing treatment response monitoring.
